American Association for Clinical Chemistry
Better health through laboratory medicine
May 2009 Clinical Laboratory News: Industry Profiles

CLN Banner Logo

May 2009: Volume 35, Number 5

Seegene Announces Licensing Agreement with Randox

Seegene has agreed to grant Randox Laboratories a non-exclusive license to Seegene’s Dual Priming Oligo (DPO) technology to develop high-throughput diagnostic screening panels capable of detecting pathogens that can cause either respiratory or sexually transmitted diseases. The agreement brings together Seegene’s DPO multiplex PCR technology and Randox’s Biochip Array Technology to facilitate highly sensitive and specific detection of a broad range of pathogens from a single patient sample. In a joint statement, Dr. Jong-Yoon Chun, CEO of Seegene, and Dr. Peter Fitzgerald, managing director of Randox, stated that “the tests that are developed will provide clinical laboratories with a diagnostic system capable of detecting more infections with unparalleled accuracy and speed.” Financial terms of the agreement were not disclosed.

Cleveland Clinic Plans National Expansion of Reference Lab Services

Cleveland Clinic will begin an expansion of its reference lab, a move that will allow for the growth of the Pathology and Laboratory Institute at Cleveland Clinic. In the new 100,000-square-foot lab, staff will perform molecular diagnostics and esoteric tests that will be marketed internationally. “This expansion will help enhance patient care by allowing us to provide more sophisticated testing with a faster turnaround time on results,” said Kandice Kottke-Marchant, MD, PhD, Chair of the Pathology and Laboratory Medicine Institute. “It will also open up new research and test development opportunities in molecular and DNA testing.” Construction is expected to begin by mid-2009, with the lab opening by the end of 2010. The project is expected to create 500 new jobs within the next 5 years.

Biomarker Deal Signed Between Bio-Rad, Bruker

Bio-Rad and Bruker have signed an exclusive partnership to develop and market new products based on Bio-Rad’s surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker’s matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometers for applications of high-throughput protein profiling and identification. The new products are intended to be used in biomarker discovery, particularly for the detection and identification of intact peptides and proteins under 30 kDa.

Beckman Coulter to Acquire Clinical Data’s Genomics Unit

Drug developer Clinical Data has agreed to sell Cogenics, its genomic division that has operations in the U.S., U.K., Germany and France, to Beckman Coulter for approximately $17 million. Cogenics products include current and next-generation sequencing, gene expression, clinical and nonclinical genotyping, biomanufacturing support, nucleic acid extraction, and biobanking. In a press release, Beckman Coulter said the acquisition complements its Agencourt Biosciences unit and expands the company’s product line into new markets.

Siemens, Sysmex Renew Global Agreement

Siemens Healthcare and Sysmex have signed a 5-year contract renewal agreement allowing clinical lab customers around the world to have access to the largest portfolio of coagulation instruments and tests. The wide variety of coagulation instruments and tests covered in this agreement are used by clinical labs to test for blood disorders or to monitor patients on blood-thinning medication. The agreement also includes access to automated platelet function testing. The two companies will also continue joint product development efforts related to new coagulation technology.